ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Synlogic Inc

Synlogic Inc (SYBX)

1.46
-0.09
( -5.81% )
Updated: 14:40:22

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.46
Bid
1.47
Ask
1.51
Volume
60,104
1.35 Day's Range 1.59
0.00 52 Week Range 0.00
Market Cap
Previous Close
1.55
Open
1.59
Last Trade
61
@
1.51
Last Trade Time
14:33:36
Financial Volume
$ 90,760
VWAP
1.51
Average Volume (3m)
-
Shares Outstanding
9,189,353
Dividend Yield
-
PE Ratio
-0.24
Earnings Per Share (EPS)
-6.23
Revenue
3.37M
Net Profit
-57.28M

About Synlogic Inc

Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are ... Synlogic Inc is a biopharmaceutical company focused on the discovery and development of Synthetic Biotic medicines which are designed to metabolize a toxic substance, compensate for missing or damaged metabolic pathways, or deliver combinations of therapeutic factors. Synthetic Biotic medicines are generated from the company's proprietary drug discovery and development platform, using Synthetic Biology and leveraging a reproducible, modular approach to develop beneficial microbes that perform or deliver critical therapeutic functions. Its key product candidate is SYNB1618, an oral therapy intended for the treatment of PKU, a rare metabolic disease in which an amino acid known as phenylalanine accumulates in the body as a result of genetic defects. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Synlogic Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker SYBX. The last closing price for Synlogic was $1.55. Over the last year, Synlogic shares have traded in a share price range of $ 0.00 to $ 0.00.

Synlogic currently has 9,189,353 shares outstanding. The market capitalization of Synlogic is $13.88 million. Synlogic has a price to earnings ratio (PE ratio) of -0.24.

SYBX Latest News

Synlogic Reports First Quarter 2024 Financial Results

CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today...

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

CAMBRIDGE, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GRDIGRIID Infrastructure Inc
$ 1.52
(171.43%)
138.65M
ZAPPZapp Electric Vehicles Group Ltd
$ 3.0447
(123.88%)
86.7M
MGOLMGO Global Inc
$ 0.7621
(66.25%)
153.05M
RELIReliance Global Group Inc
$ 0.5664
(44.82%)
121.25M
MOLNMolecular Partners AG
$ 10.63
(33.54%)
317.04k
WHLRWheeler Real Estate Investment Trust Inc
$ 2.705
(-82.79%)
147.48k
KAVLKaival Brands Innovations Group Inc
$ 2.78
(-38.22%)
1.03M
MBIOMustang Bio Inc
$ 0.5485
(-35.48%)
35.64M
NLSPNLS Pharmaceutics Ltd
$ 0.1802
(-33.28%)
13.4M
TPSTTempest Therpeutics Inc
$ 1.96
(-31.23%)
29.79M
NVDANVIDIA Corporation
$ 132.51
(-2.26%)
399.39M
NKLANikola Corporation
$ 0.345
(-28.26%)
221.47M
SMXSMX Security Matters Public Company
$ 0.1538
(29.24%)
167.44M
MGOLMGO Global Inc
$ 0.7621
(66.25%)
153.05M
GRDIGRIID Infrastructure Inc
$ 1.52
(171.43%)
138.65M

SYBX Discussion

View Posts
Monksdream Monksdream 3 months ago
SYBX under $2
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
SYBX under $2
πŸ‘οΈ0
Monksdream Monksdream 4 months ago
SYBX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
SYBX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
SYBX new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 9 months ago
SYBX new 52 week low
πŸ‘οΈ0
l2 hunter l2 hunter 11 months ago
SYBX 0.55 +9% after 0.56 looks like breakout coming..


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AAPL
AHRO
AITX
AMC
AMIH
ATMH
AVXL
BDPT
BTTX
CBD
CDSG
CLNV
CORZQ
CRGP
CYXTQ
DBMM
DLOC
DWAC
ECDD
ENZC
EPAZ
FTEG
GEGI
GRST
GVSI
HHSE
IFUS
INKW
IQST
JPM
LWLG
MGOL
MGRX
MIKP
MMTMF
MMY
MSFT
MULN
NSAV
NWBO
PWM
RIVN
RNVA
SNPW
SNTX
SRMX
TMC
TSLA
TTOO
XCRT
πŸ‘οΈ0
AJ Freely AJ Freely 11 months ago
$SYBX - Up 9% Pre-Market/ Current Price $0.55
Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria
πŸ‘οΈ0
l2 hunter l2 hunter 11 months ago
SYBX 0.554 +10%


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AAPL
AHRO
AITX
AMC
AMIH
ATMH
AVXL
BDPT
BTTX
CBD
CDSG
CLNV
CORZQ
CRGP
CYXTQ
DBMM
DLOC
DWAC
ECDD
ENZC
EPAZ
FTEG
GEGI
GRST
GVSI
HHSE
IFUS
INKW
IQST
JPM
LWLG
MGOL
MGRX
MIKP
MMTMF
MMY
MSFT
MULN
NSAV
NWBO
PWM
RIVN
RNVA
SNPW
SNTX
SRMX
TMC
TSLA
TTOO
XCRT
πŸ‘οΈ0
Monksdream Monksdream 12 months ago
SYBX new 52 week low
πŸ‘οΈ0
Triple nickle Triple nickle 1 year ago
smh why this baby’s not running
πŸ‘οΈ0
J2003 J2003 1 year ago
Why is it not running?
πŸ‘οΈ0
subslover subslover 1 year ago
Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).

β€œWe are very pleased that SYNB1934 has been granted another regulatory designation, further validating the need for new treatment options for those living with PKU,” said Aoife Brennan M.B. Ch.B., Synlogic President and Chief Executive Officer. β€œThis designation also comes at a pivotal time as we prepare to initiate our Phase 3 trial for PKU – Synpheny-3β€” in the first half of this year.”

ODD is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, which generally affects less than 200,000 individuals in the U.S. ODD granted therapies entitle companies to development incentives including tax credits for qualified clinical trials, user fee exemptions, and the potential for seven years of market exclusivity after approval.

SYNB1934 has also received Rare Pediatric Disease Designation (RPDD) from the FDA and orphan designation from the European Medicines Agency (EMA).

About SYNB1934

SYNB1934 is an orally administered, non-systemically absorbed drug candidate being studied as potential biotherapeutic for phenylketonuria (PKU). PKU is an inherited rare metabolic disease caused by an inborn error of metabolism that impairs the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods. Treatment options for PKU are currently limited, with a majority of individuals with PKU in need of treatment or not adequately responding to treatment. Synlogic designed SYNB1934 to reduce levels of Phe in people with PKU by consuming Phe in the gastrointestinal (GI) tract, using genetic engineering of the well-characterized probiotic E. coli Nissle. Findings to date support the potential for an oral, efficacious, safe, convenient, and flexible treatment option for PKU. SYNB1934 has been granted Rare Pediatric Disease and Orphan Drug designations by the U.S. Food and Drug Administration (FDA) and orphan designation from the European Medicines Agency (EMA).

About Synlogic

Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includ
πŸ‘οΈ0
ShortSale4U ShortSale4U 2 years ago
Still here. I think this is finally bottoming out. Good luck all !
πŸ‘οΈ0
ShortSale4U ShortSale4U 3 years ago
Good morning Synlogic Shareholders , future investors and visitors. Today the stars may align and bless us with profits. with the continued low asking price along with Charden"s upgrade from 5 to a 10 dollar stock making this stock ready to run. Good luck all!
πŸ‘οΈ0
ShortSale4U ShortSale4U 3 years ago
Welcome and good luck .this stock is poise to run if we can just get the news out low shares on the ask.
πŸ‘οΈ0
Stonkenstein Stonkenstein 3 years ago
Grabbed a starter yesterday.
πŸ‘οΈ0
ShortSale4U ShortSale4U 3 years ago
If this news gets out , it may have a chance to double. have to wait and see.
πŸ‘οΈ0
ShortSale4U ShortSale4U 3 years ago
The news need to spread to get this stock moving!
πŸ‘οΈ0
ShortSale4U ShortSale4U 3 years ago

"*Synlogic shares are trading higher after Chardan raised its price target on the stock from $5 to $10.
Benzinga"
This stock is under the radar!
πŸ‘οΈ0
ShortSale4U ShortSale4U 3 years ago
There's news out today!
πŸ‘οΈ0
ShortSale4U ShortSale4U 3 years ago
Hey is any one here
πŸ‘οΈ0
ClayTrader ClayTrader 4 years ago
* * $SYBX Video Chart 12-14-2020 * *

Link to Video - click here to watch the technical chart video

πŸ‘οΈ0
RNsidersbuying RNsidersbuying 4 years ago
https://www.cnbc.com/video/2019/06/13/ginkgo-bioworks-and-synlogic-to-collaborate-on-living-medicine.html
πŸ‘οΈ0
RNsidersbuying RNsidersbuying 4 years ago
On June 11, 2019, Synlogic, Inc. (the β€œ Company ”) entered into a Subscription Agreement (the β€œ Subscription Agreement ”) with Ginkgo Bioworks, Inc. (β€œ Ginkgo ”), providing for the issuance and sale by the Company to Ginkgo of an aggregate of (i) 6,340,771 shares (the β€œ Shares ”) of the Company’s common stock, par value $0.001 per share (the β€œ Common Stock ”), at a purchase price per Share of $9.00, and (ii) pre-funded warrants to purchase an aggregate of 2,548,117 shares of Common Stock (the β€œ Pre-Funded Warrants ”) at an exercise price of $9.00 per Share (the β€œ Offering ”), with $8.99 of such exercise price paid at the closing of the Offering. The gross proceeds to the Company will be approximately $80 million. The closing of the Offering took place on June 11, 2019.

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13487245&RcvdDate=6/12/2019&CoName=SYNLOGIC,%20INC.&FormType=8-K&View=html
πŸ‘οΈ0
RNsidersbuying RNsidersbuying 4 years ago
11/25/2020 Day Chart:

πŸ‘οΈ0
RNsidersbuying RNsidersbuying 4 years ago
Synlogic has a platform collaboration agreement with Ginkgo Bioworks to aid in strain optimization and development.

https://www.synlogictx.com/collaborations/

NOVEMBER 25, 2020
U.S. loans $1.1 billion to Ginkgo Bioworks for pandemic effort

https://www.reuters.com/article/idUSKBN2851TA
πŸ‘οΈ0
RNsidersbuying RNsidersbuying 4 years ago
https://www.secform4.com/insider-trading/1527599.htm
πŸ‘οΈ0
RNsidersbuying RNsidersbuying 4 years ago
SYBX 1.85 - currently trading at less than 1/2 cash with several programs in the pipeline...

SARS-CoV2 Vaccine Initiative

Synlogic is evaluating its Synthetic Biotic platform for the development of a vaccine for the prevention of SARS-CoV2.

https://www.synlogictx.com/pipeline-programs/#sars
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock